Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases

被引:3
作者
Tashakori, Mehrnoosh [1 ]
Kim, Do Hwan [1 ]
Kanagal-Shamanna, Rashmi [1 ]
Vega, Francisco [1 ]
Miranda, Roberto N. [1 ]
Jain, Preetesh [2 ]
Wang, Michael [2 ]
Medeiros, L. Jeffrey [1 ]
Ok, Chi Young [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
关键词
Mantle cell lymphoma; Tonsil; Limited-stage; extranodal; low-risk MIPI; GASTROINTESTINAL INVOLVEMENT; SURVIVAL;
D O I
10.1016/j.humpath.2021.10.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We report 83 cases of mantle cell lymphoma (MCL) involving the tonsil as initial manifestation (IM). The median age at the time of tonsillar involvement was 58 years (range, 35-79 years). Most (85%) patients presented similar to acute tonsillitis. Lymphadenopathy (84%) and advanced stage of disease (81%) were frequent. With a median follow-up of 6.1 years (range, 0.5-18.4 years), the median overall survival (OS) was 11.3 years for all patients. Cases with classic MCL morphology demonstrated a superior OS (median OS: 11.7 years versus 7.8 years for aggressive morphology, P = 0.0361). Approximately 20% of patients had limited stage of disease, and they had excellent outcomes (median OS: not reached versus 11.3 years for advanced-stage MCL, P = 0.0479). All the patients were alive after a median follow-up of 6.6 years (range, 1-16.2 years). There were no differences in relapse-free survival in morphology and stage (P > 0.05). When tonsils were involved by relapsed MCL, patients less commonly had acute tonsillitis -like symptoms, lymphadenopathy, and advanced stage of disease compared to MCL as IM. Patients in the relapse group had poorer OS than patients in the IM group from the time of tonsillar involvement by MCL to the date of death or last follow-up (7.8 versus 11.7 years, P = 0.003). Compared with a group of 93 patients whose initial biopsy specimen was a lymph node, patients whose initial biopsy specimen was tonsil had similar OS (11.7 versus 8.8 years, P = 0.1764). However, patients with tonsillar MCL more commonly had limited stage disease (19% versus 8%, P = 0.0385) and a low-risk Mantle Cell Lymphoma International Prognostic Index score (71% versus 47%, P = 0.0025). (C) 2021 Published by Elsevier Inc.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 50 条
  • [41] Watch and Wait in Mantle Cell Lymphoma
    Lee, Christina
    Martin, Peter
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (05) : 837 - 847
  • [42] Bortezomib in the treatment of mantle cell lymphoma
    Robak, Tadeusz
    FUTURE ONCOLOGY, 2015, 11 (20) : 2807 - 2818
  • [43] Diagnosis and treatment of mantle cell lymphoma
    Hitz, Felicitas
    Bargetzi, Mario
    Cogliatti, Sergio
    Lohri, Andreas
    Taverna, Christian
    Renner, Christoph
    Mey, Ulrich
    SWISS MEDICAL WEEKLY, 2013, 143
  • [44] Mantle cell lymphoma epidemiology: a population-based study in France
    Christophe Leux
    Marc Maynadié
    Xavier Troussard
    Quentin Cabrera
    Aurélie Herry
    Sandra Le Guyader-Peyrou
    Steven Le Gouill
    Alain Monnereau
    Annals of Hematology, 2014, 93 : 1327 - 1333
  • [45] Mantle cell lymphoma epidemiology: a population-based study in France
    Leux, Christophe
    Maynadie, Marc
    Troussard, Xavier
    Cabrera, Quentin
    Herry, Aurelie
    Le Guyader-Peyrou, Sandra
    Le Gouill, Steven
    Monnereau, Alain
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1327 - 1333
  • [46] Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
    Morello, Lucia
    Rattotti, Sara
    Giordano, Laura
    Jerkeman, Mats
    van Meerten, Tom
    Krawczyk, Katarzyna
    Moita, Filipa
    Marino, Dario
    Ferrero, Simone
    Szymczyk, Michal
    Aurer, Igor
    El-Galaly, Tarec Christoffer
    Di Rocco, Alice
    Visco, Carlo
    Carli, Giuseppe
    Defrancesco, Irene
    Carlo-Stella, Carmelo
    Dreyling, Martin
    Santoro, Armando
    Arcaini, Luca
    HEMASPHERE, 2020, 4 (01):
  • [47] Mantle cell lymphoma
    Sander, Birgitta
    SEMINARS IN CANCER BIOLOGY, 2011, 21 (05) : 291 - 292
  • [48] Mantle cell lymphoma
    Pileri, Stefano A.
    Falini, Brunangelo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11): : 1488 - 1492
  • [49] Using primary site as a predictor of survival in mantle cell lymphoma
    Ambinder, Alexander J.
    Shenoy, Pareen J.
    Nastoupil, Loretta J.
    Flowers, Christopher R.
    CANCER, 2013, 119 (08) : 1570 - 1577
  • [50] Mantle cell lymphoma as a rare cause of intussusception: a report of 2 cases
    Grin, Andrea
    Chetty, Runjan
    Bailey, Denis
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2009, 13 (06) : 398 - 401